SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
Sexual HealthResearch-onlyVendors pending
Research-onlyVendors pendingFacts verified · 2026-05-25

Prostamax

Also known as prostamax

Prostamax is a Khavinson short-peptide bioregulator marketed for prostate health, consisting of a tripeptide (Ala-Glu-Asp, AED) derived from prostate-tissue extracts. It is sold in Russia as both an oral capsule and a parenteral preparation, and is popular in longevity research circles for its proposed support of prostate function, glandular metabolism, and urinary parameters. There are no published Western controlled trials, no FDA approval, and clinical evidence is confined to Russian-language literature from the Khavinson institute. Treat as investigational only outside Russia.

—

best

price

—

per

mg

—

vendors

tracked

Research-only

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Prostamax is described as a Khavinson AED tripeptide bioregulator. The proposed mechanism (Khavinson, PMID 27909961) is tissue-specific gene-expression modulation: direct interaction with promoter regions of prostate-epithelium genes to normalize cell metabolism, support healthy glandular function, and improve urinary parameters.

Prostamax is described as a Khavinson AED tripeptide bioregulator. The proposed mechanism (Khavinson, PMID 27909961) is tissue-specific gene-expression modulation: direct interaction with promoter regions of prostate-epithelium genes to normalize cell metabolism, support healthy glandular function, and improve urinary parameters. No classical receptor target is defined, and the 'short peptide enters cell, translocates to nucleus, binds DNA' model remains unconfirmed in independent Western structural biology. Russian preclinical work suggests modest effects on prostate epithelial proliferation markers (Khavinson, PMID 19827673), but independent replication is absent.

Pharmacokinetic properties

Half-life

Unknown — no published human PK data

Routes

subcutaneous · intramuscular · oral

Bioavailability

Oral capsule formulations are sold in Russia; parenteral bioregulator (peptide injectable) is used in research. Oral bioavailability of a short tripeptide is plausibly modest via PepT1 but unvalidated.

Amino-acid sequence

H2N-CH[(CH2)4NH2]-CO-NH-CH[(CH2)2COOH]-COOH

Use & research dosing

Healthy Aging

Russian protocols and self-experimentation reports commonly use 100-300 mcg subcutaneous daily for 10-20 day cycles, repeated 1-2 times per year. Russian oral capsules are typically labeled around 200 mcg total peptide content per capsule, dosed once or twice daily over the same cycle length. No FDA-approved dose exists and no Western pharmacokinetic data are available to validate any particular schedule. Research framing only.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Current state: Prostamax sits within the Khavinson bioregulator framework, with all the usual caveats — minimal independent replication, no Western controlled trials, and a mechanistic model that has not been confirmed by mainstream structural biology. Marketed claims around prostate function and urinary parameters should be treated as preliminary and not as a substitute for evidence-based urologic care.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Active or suspected prostate cancer — no safety data; avoid
  • Almost all efficacy data come from the Khavinson group; independent replication essentially absent
  • No published Western human PK or controlled safety data — limited safety data flag
  • Not a substitute for evaluation of BPH, urinary obstruction, or PSA elevation
  • Pediatric use and use in non-target populations — no data
  • Vendor purity, peptide identity, and endotoxin levels variable
  • Mechanistic claim of direct DNA binding by short peptides is unverified independently

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/19827673/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/27909961/

Facts verified

2026-05-25

Confidence

low

What this means

  • evidence base is primarily Russian-language / Khavinson institute
  • limited safety data
  • no Western controlled trials
  • mechanistic claims unverified independently

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.